← All organizations

Puma Biotechnology, Inc.

For profitContributed to NMEWebsite ↗

Also known as: PUMA BIOTECH | Puma Biotechnology, Inc. | Ruth O'Regan

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

First marketed drug

First NDA

Last known activity

Jan 31, 2025

Timeline

2000s

Jul 1, 2007
Puma Biotechnology, Inc.— Founded

2010s

Jul 17, 2017
neratinib maleate— NDA Organization
Jul 17, 2017
neratinib maleate— NDA Secondary Org

Drugs by trial phase (40 distinct, 56 trials)

Phase 3 (3 own, 0 via acquisition)

Phase 2 (29 own, 0 via acquisition)

Phase 1 (8 own, 0 via acquisition)

Indications

Approved for

Breast Neoplasms

Studied for

Marketed drugs (1)

neratinib maleate

Recent trials (50)

NCT05919108CollaboratorPhase 2Jan 31, 2025
NCT06369285OfficialPhase 2Dec 31, 2024
NCT06369285Lead sponsorPhase 2Dec 31, 2024
NCT06109467CollaboratorPhase 2Jan 12, 2024
NCT06095505Study directorPhase 2Dec 31, 2023
NCT06095505Lead sponsorPhase 2Dec 31, 2023
NCT05252988CollaboratorPhase 2Aug 31, 2022
NCT05243641CollaboratorPhase 1/Phase 2Aug 18, 2022
NCT05274048CollaboratorPhase 1Jun 24, 2022
NCT04901299CollaboratorPhase 2Dec 31, 2021
NCT04886531Lead sponsorPhase 2Jun 30, 2021
NCT04886531CollaboratorPhase 2Jun 30, 2021
NCT04781374CollaboratorPhase 2May 21, 2021
NCT04502602CollaboratorPhase 1Aug 24, 2020
NCT04366713Study directorPhase 2Jun 30, 2020

Details

Founded: Los Angeles, CA, US Jul 1, 2007
First NDA: Jul 17, 2017
Last known activity: Jan 31, 2025